NCT02864290: A trial that was reported late by Astellas Pharma Global Development, Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT02864290 |
|---|---|
| Title | A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 10, 2016 |
| Completion date | Sept. 3, 2020 |
| Required reporting date | Sept. 3, 2021, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 7, 2021 |
| Days late | 33 |